From Science to Impact with Biogen CEO Chris Viehbacher

The science behind rare disease treatments is advancing at an unprecedented pace. Biogen is sharpening its long-term strategy to lead in the next era of innovation, including ensuring next-generation therapies deliver greater efficacy and durability for patients. CEO, Chris Viehbacher talks about how the company is expanding its global footprint and diversifying its pipeline, all while navigating a rapidly evolving regulatory environment.